Kempharm Stock Today

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Kempharm is trading at 10.75 as of the 29th of July 2021. This is a -2.18% down since the beginning of the trading day. The stock's open price was 10.99. Kempharm has a very small chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for Kempharm are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of March 2021 and ending today, the 29th of July 2021. Click here to learn more.
 Market Performance
5 of 100
  Odds Of Distress
Less than 3

Kempharm Stock Profile

The upcoming quarterly report is expected on the 11th of August 2021. KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. more on Kempharm
Kempharm has very high historical volatility over the last 90 days
Kempharm was previously known as Kempharm and was traded on NASDAQ Exchange under the symbol KMPHD.
The company reported the previous year's revenue of 23.32 M. Net Loss for the year was (54.75 M) with profit before overhead, payroll, taxes, and interest of 11.98 M.
Kempharm currently holds about 75.92 M in cash with (2.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.66.
Kempharm has a frail financial position based on the latest SEC disclosures
Roughly 15.0% of the company outstanding shares are owned by corporate insiders
Latest headline from KMPH KemPharm Announces U.S. Launch Of Innovative ADHD Treatment Azstarys By Corium - CML News
Kempharm Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Kempharm SEC Filings
Kempharm SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameKempharm
Older SymbolKMPHD
ChairmanTravis Mickle  (View All)
Average Analyst Recommendation
Analysts covering Kempharm report their recommendations after researching Kempharm's financial statements, talking to executives and customers, or listening in on Kempharm's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Kempharm. The Kempharm consensus assessment is calculated by taking the average forecast from all of the analysts covering Kempharm.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Kempharm based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Kempharm financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares4.3 MM
Significantly Up
Slightly volatile
Weighted Average Shares Diluted4.3 MM
Significantly Up
Slightly volatile
Total Assets11.5 M11.2 M
Fairly Up
Total Liabilities82.9 M77.6 M
Notably Up
Slightly volatile
Current Assets8.6 M8.4 M
Fairly Up
Current Liabilities8.4 M7.5 M
Significantly Up
Slightly volatile
Total Debt70.5 M70.4 M
Slightly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Asset Turnover1.261.218
Sufficiently Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Kempharm's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Kempharm's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Kempharm's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kempharm's financial leverage. It provides some insight into what part of Kempharm's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Kempharm's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Kempharm deploys its capital and how much of that capital is borrowed.
Kempharm cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.75 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kempharm has a current ratio of 20.29, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(2.09 Million)Share
Kempharm (KMPH) is traded on NASDAQ Exchange in USA. It is located in 1180 Celebration Boulevard and employs 22 people. Kempharm was previously known as Kempharm and was traded on NASDAQ Exchange under the symbol KMPHD. Kempharm is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 306.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kempharm's market, we take the total number of its shares issued and multiply it by Kempharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Kempharm conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 28.51 M outstanding shares of which 3.55 M shares are now shorted by private and institutional investors with about 6.11 trading days to cover. Kempharm currently holds about 75.92 M in cash with (2.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.66.
Check Kempharm Probability Of Bankruptcy
Kempharm maintains a total of twenty-eight million five hundred ten thousand outstanding shares. Kempharm secures 14.73 % if its outstanding shares held by insiders and 14.73 % owned by institutional investors . Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Kempharm Ownership Details

Kempharm Stock Price Odds Analysis

What are Kempharm's target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Kempharm jumping above the current price in 90 days from now is about 63.64%. The Kempharm probability density function shows the probability of Kempharm stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Kempharm has a beta of 0.7881. This indicates as returns on the market go up, Kempharm average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Kempharm will be expected to be much smaller as well. Additionally, the company has an alpha of 0.2689, implying that it can generate a 0.27 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 10.75HorizonTargetOdds Up 10.75 
36.26%90 days
Based on a normal probability distribution, the odds of Kempharm to move above the current price in 90 days from now is about 63.64 (This Kempharm probability density function shows the probability of Kempharm Stock to fall within a particular range of prices over 90 days) .

Kempharm Historical Income Statement

Kempharm Income Statement is one of the three primary financial statements used for reporting Kempharm's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Kempharm revenue and expense. Kempharm Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Kempharm Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 7.92 Million. The current Weighted Average Shares is estimated to increase to about 4.3 M, while Consolidated Income is projected to decrease to (13.8 M). View More Fundamentals

Kempharm Stock Against Markets

Picking the right benchmark for Kempharm stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Kempharm stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Kempharm is critical whether you are bullish or bearish towards Kempharm at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kempharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Center Now


Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Kempharm Corporate Directors

Kempharm corporate directors refer to members of a Kempharm board of directors. The board of directors generally takes responsibility for the Kempharm's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Kempharm's board members must vote for the resolution. The Kempharm board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
David Tierney - Independent DirectorProfile
Joseph Saluri - Independent DirectorProfile
Matthew Plooster - Independent DirectorProfile
Richard Pascoe - Lead Independent DirectorProfile
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.